Unknown

Dataset Information

0

Immuno-pharmacological characterization of group II metabotropic glutamate receptors controlling glutamate exocytosis in mouse cortex and spinal cord.


ABSTRACT: BACKGROUND AND PURPOSE:We recently proposed the existence of mGlu3 -preferring autoreceptors in spinal cord terminals and of mGlu2 -preferring autoreceptors in cortical terminals. This study aims to verify our previous conclusions and to extend their pharmacological characterization. EXPERIMENTAL APPROACH:We studied the effect of LY566332, an mGlu2 receptor positive allosteric modulator (PAM), and of LY2389575, a selective mGlu3 receptor negative allosteric (NAM) modulator, on the mGlu2/3 agonist LY379268-mediated inhibition of glutamate exocytosis [measured as KCl-evoked release of preloaded [3 H]-D-aspartate]. The mGlu2 PAM BINA and the mGlu3 NAM ML337, as well as selective antibodies recognizing the N-terminal of the receptor proteins, were used to confirm the pharmacological characterization of the native receptors. KEY RESULTS:Cortical synaptosomes possess LY566332-sensitive autoreceptors that are slightly, although significantly, susceptible to LY2389575. In contrast, LY566332-insensitive and LY2389575-sensitive autoreceptors are present in spinal cord terminals. BINA and ML337 mimicked LY566332 and LY2389575, respectively, in controlling LY379268-mediated inhibition of glutamate exocytosis from both cortical and spinal cord synaptosomes. Incubation of cortical synaptosomes with anti-mGlu2 antibody prevented the LY379268-induced inhibition of glutamate exocytosis, and this response was partially reduced by the anti-mGlu3 antibody. Incubation of spinal cord synaptosomes with the anti-mGlu3 antibody abolished LY379268-mediated reduction of glutamate exocytosis from these terminals, while the anti-mGlu2 antibody was inactive. Western blot analysis and confocal microscopy data were largely consistent with these functional observations. CONCLUSIONS AND IMPLICATIONS:We confirmed that mGlu3 -preferring autoreceptors exist in spinal cord terminals. Differently, cortical glutamatergic terminals possess mGlu2 /mGlu3 heterodimers, whose inhibitory effect is largely mediated by mGlu2 receptors.

SUBMITTER: Olivero G 

PROVIDER: S-EPMC5727332 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Immuno-pharmacological characterization of group II metabotropic glutamate receptors controlling glutamate exocytosis in mouse cortex and spinal cord.

Olivero Guendalina G   Bonfiglio Tommaso T   Vergassola Matteo M   Usai Cesare C   Riozzi Barbara B   Battaglia Giuseppe G   Nicoletti Ferdinando F   Pittaluga Anna A  

British journal of pharmacology 20171029 24


<h4>Background and purpose</h4>We recently proposed the existence of mGlu<sub>3</sub> -preferring autoreceptors in spinal cord terminals and of mGlu<sub>2</sub> -preferring autoreceptors in cortical terminals. This study aims to verify our previous conclusions and to extend their pharmacological characterization.<h4>Experimental approach</h4>We studied the effect of LY566332, an mGlu<sub>2</sub> receptor positive allosteric modulator (PAM), and of LY2389575, a selective mGlu<sub>3</sub> receptor  ...[more]

Similar Datasets

| S-EPMC2628285 | biostudies-literature
| S-EPMC6673797 | biostudies-literature
| S-EPMC2902553 | biostudies-literature
| S-EPMC3681425 | biostudies-literature
| S-EPMC3631455 | biostudies-literature
| S-EPMC4562903 | biostudies-literature
| S-EPMC2792875 | biostudies-literature
| S-EPMC7818470 | biostudies-literature
| S-EPMC321022 | biostudies-other
| S-EPMC1909512 | biostudies-other